Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?

Med (New York, N.Y.) - 14 Aug 2026

Orsi Giulia, Reni Michele

Abstract excerpt

The phase 3 RASolute 302 trial demonstrated significant overall and progression-free survival benefits with daraxonrasib over investigator's choice chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma harboring RAS G12 mutations after progression on prior chemotherapy.1 The benefit in patients with non-G12 RAS mutations or RAS wild-type tumors remains unclear.

Topics

Join the communities discussing this publication.

Mutation
Pancreatic Neoplasms
Antineoplastic Agents
Benzamides
Carcinoma, Pancreatic Ductal
Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 42600570
DOI: 10.1016/j.medj.2026.101227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?PMID 42600570Read ↗

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.Semantic proximity Read ↗

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.Semantic proximity Read ↗

KRAS Inhibition in Pancreatic Cancer: Pooled Efficacy and Safety Signals from Early-Phase StudiesSemantic proximity Read ↗

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer.Semantic proximity Read ↗

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic CancerSemantic proximity Read ↗

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.Semantic proximity Read ↗

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity Read ↗

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Semantic proximity Read ↗

Sotorasib as Fourth-Line Treatment in Pancreatic Cancer: A Case Report and Literature Review.Semantic proximity Read ↗

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.